Edition:
United Kingdom

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

20.63USD
18 Jan 2019
Change (% chg)

$0.73 (+3.67%)
Prev Close
$19.90
Open
$19.93
Day's High
$20.65
Day's Low
$19.75
Volume
267,781
Avg. Vol
522,943
52-wk High
$36.63
52-wk Low
$11.66

Latest Key Developments (Source: Significant Developments)

FDA declines to approve reformulated Mallinckrodt opioid
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT'S SPECGX LLC RECEIVES FDA COMPLETE RESPONSE LETTER FOR ABUSE-DETERRENT, IMMEDIATE-RELEASE REFORMULATION OF ROXICODONE® (OXYCODONE HYDROCHLORIDE).MALLINCKRODT - IN LETTER, FDA PROVIDED GUIDANCE REGARDING AREAS OF FURTHER EVALUATION NECESSARY TO RESUBMIT NDA FOR FURTHER REVIEW.MALLINCKRODT PLC - EVALUATING FDA'S LETTER AND WILL REQUEST A MEETING IN COMING WEEKS TO DISCUSS IT FURTHER.  Full Article

Mallinckrodt Plans Spin-Off Of Specialty Generics Business To Shareholders
Thursday, 6 Dec 2018 

Mallinckrodt Plc ::MALLINCKRODT PLANS SPIN-OFF OF SPECIALTY GENERICS BUSINESS TO SHAREHOLDERS.MALLINCKRODT PLC - TRANSACTION EXPECTED TO BE COMPLETED IN SECOND HALF OF 2019.MALLINCKRODT PLC - SPUN-OFF COMPANY WILL ASSUME MALLINCKRODT NAME; SPECIALTY PHARMACEUTICAL BRANDS COMPANY WILL BE RENAMED.MALLINCKRODT PLC - PLANNED SEPARATION IS EXPECTED TO BE EXECUTED THROUGH A PRO-RATA DISTRIBUTION OF COMMON STOCK TO MALLINCKRODT'S SHAREHOLDERS.MALLINCKRODT PLC - TRANSACTION EXPECTED TO CREATE TWO DIFFERENTIATED PHARMACEUTICAL COMPANIES WITH SCALE.MALLINCKRODT PLC - HARBAUGH WILL STEP DOWN AS MALLINCKRODT'S CFO, EFFECTIVE IMMEDIATELY.MALLINCKRODT PLC - SPUN-OFF COMPANY WILL BE LISTED ON NYSE AND WILL ASSUME MALLINCKRODT NAME AND TICKER SYMBOL (MNK).MALLINCKRODT PLC - MATTHEW HARBAUGH IS EXPECTED TO BECOME PRESIDENT AND CHIEF EXECUTIVE OFFICER OF NEW COMPANY UPON COMPLETION OF SPIN OFF..MALLINCKRODT PLC - DURING THIS PROCESS, GEORGE KEGLER, MALLINCKRODT'S VICE PRESIDENT OF FINANCE, WILL SERVE AS INTERIM CFO.MALLINCKRODT PLC - GEORGE KEGLER WILL SERVE AS INTERIM CFO.MALLINCKRODT - REMAINING SPECIALTY PHARMACEUTICAL BRANDS CO TO CONTINUE TO FOCUS ON ITS PORTFOLIO OF INNOVATIVE MARKETED & DEVELOPMENT PRODUCT.  Full Article

Hill-Rom Announces Executive Appointments
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Hill-Rom Holdings Inc ::HILL-ROM ANNOUNCES EXECUTIVE APPOINTMENTS.HILL-ROM HOLDINGS INC - BARBARA BODEM TO SUCCEED STEVEN J. STROBEL AS CFO.HILL-ROM HOLDINGS INC - MARY KAY LADONE APPOINTED SENIOR VICE PRESIDENT, CORPORATE DEVELOPMENT, STRATEGY AND INVESTOR RELATIONS.HILL-ROM HOLDINGS INC - ANDREAS FRANK TO SUCCEED ALTON SHADER AS PRESIDENT OF HILL-ROM'S FRONT LINE CARE BUSINESS.HILL-ROM HOLDINGS INC - BODEM JOINS HILL-ROM FROM MALLINCKRODT.  Full Article

Mallinckrodt And NPXe Announce FDA Fast Track Designation For Phase 3 Trial Of Inhaled Xenon Gas Therapy
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT AND NPXE ANNOUNCE FDA FAST TRACK DESIGNATION FOR PHASE 3 TRIAL OF INHALED XENON GAS THERAPY.MALLINCKRODT PLC - COMPANIES ANTICIPATE TRIAL WILL COMMENCE IN COMING MONTHS, WITH FIRST PATIENTS ENROLLED IN U.S..  Full Article

Mallinckrodt Confirms Receipt Of Stannsoporfin CRL
Wednesday, 22 Aug 2018 

Aug 22 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT CONFIRMS RECEIPT OF STANNSOPORFIN COMPLETE RESPONSE LETTER.MALLINCKRODT - IN LETTER, FDA PROVIDED GUIDANCE REGARDING AREAS OF FURTHER EVALUATION FOR RESUBMITTING STANNSOPORFIN NDA.MALLINCKRODT - EVALUATING AGENCY'S GUIDANCE, TO REQUEST MEETING WITH FDA IN COMING MONTHS TO DISCUSS POTENTIAL PATHS FORWARD.MALLINCKRODT - UNTIL FDA DISCUSSION, CO DOES NOT EXPECT TO MAKE DECISION RELATED TO FUTURE EFFORTS OR INVESTMENT IN DEVELOPMENTAL PRODUCT.  Full Article

Mallinckrodt Forms Collaborative Research Partnership With Washington University
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT FORMS COLLABORATIVE RESEARCH PARTNERSHIP WITH WASHINGTON UNIVERSITY IN ST. LOUIS.MALLINCKRODT - TO FUND UP TO $10 MILLION IN COLLABORATIVE RESEARCH PROGRAMS OVER 5 YEARS TO FOCUS ON RARE DISEASES.  Full Article

Mallinckrodt Announces $300 Million Debt Repayment
Monday, 16 Apr 2018 

April 16 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT PLC ANNOUNCES $300 MILLION DEBT REPAYMENT.MALLINCKRODT PLC - COMPANY REPAYS DEBT MATURING APRIL 2018 WITH CASH ON HAND.MALLINCKRODT PLC - DEBT WAS ISSUED BY MALLINCKRODT INTERNATIONAL FINANCE SA IN 2013 IN PREPARATION FOR COMPANY'S SPIN-OFF FROM ITS FORMER PARENT.  Full Article

Mallinckrodt Will Sell Recothrom, Preveleak To Baxter for $185 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Mallinckrodt Plc :MALLINCKRODT WILL SELL RECOTHROM® AND PREVELEAK® TO BAXTER.MALLINCKRODT - TOTAL DEAL CONSIDERATION OF $185 MILLION, WITH $153 MILLION UPFRONT, INCLUDING EXISTING INVENTORY, REMAINDER IN POTENTIAL MILESTONE PAYMENTS.MALLINCKRODT PLC - WILL RETAIN RAPLIXA FOR TOPICAL USE AND IS EVALUATING STRATEGIC OPTIONS FOR THIS PRODUCT.MALLINCKRODT - ‍ SALE IS ANTICIPATED TO DILUTE CO'S ADJUSTED EARNINGS PER SHARE BY $0.10 TO $0.15 IN 2018, WHICH WILL BE OFFSET BY SHARES REPURCHASED DURING Q4 2017​.MALLINCKRODT PLC - COMPANY WILL DISCONTINUE MARKETING OF RAPLIXA UPON CLOSE OF BAXTER TRANSACTION.MALLINCKRODT PLC - PROCEEDS FROM SALE WILL BE USED BY COMPANY TOWARD PAYING DOWN DEBT.MALLINCKRODT PLC - ‍WRITE-OFF FOR RAPLIXA​ WILL BE REPORTED FOR Q4 2017.  Full Article

Baxter To Acquire Recothrom, Preveleak For Upfront Payment Of About $153 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Baxter International Inc ::BAXTER ANNOUNCES AGREEMENT TO BROADEN PORTFOLIO OF INNOVATIVE SURGICAL PRODUCTS.BAXTER INTERNATIONAL - TO ACQUIRE RECOTHROM AND PREVELEAK FOR UPFRONT PAYMENT OF ABOUT $153 MILLION AND POTENTIAL CONTINGENT PAYMENTS IN FUTURE.BAXTER INTERNATIONAL - UPON CLOSING, DEAL EXPECTED TO BE MODESTLY ACCRETIVE TO BAXTER'S 2018 ADJUSTED EPS & INCREASINGLY ACCRETIVE THEREAFTER.BAXTER INTERNATIONAL - ‍PROPOSED DEAL INCLUDES TWO HEMOSTAT & SEALANT PRODUCTS, INCLUDING STAND-ALONE RECOMBINANT THROMBIN, SURGICAL SEALANT​.  Full Article

Mallinckrodt Unit Borrowed $900 Mln Under Revolving Credit Facility
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT PLC SAYS ON DEC 29 UNIT OF CO BORROWED $900 MILLION AS A REVOLVING LOAN UNDER THE REVOLVING CREDIT FACILITY -SEC FILING.MALLINCKRODT PLC - PURSUANT TO TERMS OF CREDIT AGREEMENT, REVOLVING LOAN MATURES ON FEB 28 2022.  Full Article

U.S. lawmaker launches investigation into pharma drug pricing

WASHINGTON, Jan 14 A top U.S. lawmaker launched an investigation into pharmaceutical industry pricing practices on Monday, less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices.